Abstract
Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance during pregnancy. In Denmark the health service offers selective screening for GDM, i.e., admission to an oral glucose tolerance test (OGTT) after pre-screening with interview for clinical risk factors for GDM, two capillary fasting blood glucose (cFBG) measurements and a urine test for glucosuria. The aim of the present study was to investigate the power of the pre-screening to identify GDM and the screening to predict adverse clinical outcome.
A retrospective investigation of pregnant women undergoing screening during 1998 at Vejle County Hospital, Denmark was undertaken. The two most frequent pre-screening criteria for OGTT were body-mass index (BMI) ≥ 27 kg/m2 and age ≥ 35 years. The highest odds ratio (OR) of 9.07 (95% CI: 2.60 to 63.70) for GDM had glucosuria and the lowest (zero) had cFBG.
The frequency of complicated delivery was similar in GDM (58%) compared to non-GDM (56%). The best predictor of complicated delivery was a BMI with OR=1.50 (95% CI: 0.87 to 2.60) for BMI ≥ 27 kg/m2 vs. < 27 kg/m2. The best predictor of adverse neonatal outcome was a capillary blood glucose 120 min after glucose load (cBG120 min) ≥9.0 mmol/l (OR=3.18, 95% CI: 1.14 to 8.89). The intermediary endpoint GDM was not superior for predicting adverse maternal and neonatal outcome. The cumulative probability distribution of cBG120 min after a 75 g glucose load was not homogeneously distributed in groups stratified according to maternal and foetal outcome. A changed slope was seen after cBG120 min 9.0 mmol/l.
Screening cFBG of 4.1 mmol/l was unable to predict GDM and adverse outcome. Glucosuria was too rare to be effective as a screening tool. Pre-screening did not identify GDM. The best predictor of complicated delivery was a high BMI. The best predictor of foetal adverse outcome was cBG120 min ≥ 9.0 mmol/l after a 75 g glucose load. Identical fraction complications were present in GDM and non-GDM. A refinement of the screening procedure is highly needed, and this has been initiated in Denmark.
References
1 American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1998; 21Suppl:5–19.10.2337/diacare.21.1.S5Search in Google Scholar
2 American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 1998; 21Suppl 1:60–1.10.2337/diacare.21.1.S60Search in Google Scholar
3 World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Geneva: WHO 1999 (WHO/NCD/NCS/99.2)Search in Google Scholar
4 U.S. Preventive Service Task Force. Screening for gestational diabetes mellitus: recommendations and rationale. Obstet Gynecol 2003; 101:393–5.10.1097/00006250-200302000-00028Search in Google Scholar
5 Gabbe SG. Gestational diabetes. N Engl J Med 1986; 315:1025–6.10.1056/NEJM198610163151609Search in Google Scholar
6 O’Sullivan JB, Mahan C, Charles D, Danson R. Screening criteria for high risk gestational diabetic patients. Am J Obstet Gynecol 1973; 116:895–900.10.1016/S0002-9378(16)33833-9Search in Google Scholar
7 O’Sullivan JB, Charles D, Mahan C. Gestational diabetes and perinatal mortality rate. Am J Obstet Gynecol 1973; 116:901–4.10.1016/S0002-9378(16)33834-0Search in Google Scholar
8 Pettitt DJ, Knowler WC, Baird HR, Bennett PH. Gestational diabetes: infant and maternal complications of pregnancy in relation to third trimester glucose tolerance in the Pima Indians. Diabetes Care 1980; 3:458–64.10.2337/diacare.3.3.458Search in Google Scholar PubMed
9 Jensen DM, Damm P, Sørensen B, Mølsted-Pedersen L, Westergaard JG, Korsholm L, et al. Proposed diagnostic thresholds for gestational diabetes mellitus according to a 75-g oral glucose tolerance test. Maternal and perinatal outcomes in 3260 Danish women. Diabet Med 2003; 20:51–7.10.1046/j.1464-5491.2003.00857.xSearch in Google Scholar PubMed
10 Kaufmann RC, Smith T, Bochantin T, Khardori R, Evans MS, Steahly L. Failure to obtain follow-up testing for gestational diabetic patients in a rural population. Am J Obstet Gynecol 1999; 93:734–7.Search in Google Scholar
11 Jovanovic-Peterson L, Peterson CM. Rationale for prevention and treatment of glucose-mediated macrosomia: a protocol for gestational diabetes. Endocrinol Pract 1996; 2:118–29.10.4158/EP.2.2.118Search in Google Scholar PubMed
12 Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20:537–44.10.2337/diacare.20.4.537Search in Google Scholar PubMed
13 Danish National Board of Health. Svangreomsorg, retningslinier og redegørelse. Sundhedsstyrelsen 1998.Search in Google Scholar
14 Åberg A, Rydhström H, Källen B, Källen K. Impaired glucose tolerance during pregnancy is associated with increased fetal mortality in preceding sibs. ACTA Obstet Gynechol Scand 1997; 76:212–17.10.1111/j.1600-0412.1997.tb07847.xSearch in Google Scholar
15 Lind T. Antenatal screening using random blood glucose values. Diabetes 1985; 34:Suppl 2:17.10.2337/diab.34.2.S17Search in Google Scholar
16 Kuhl C. Glucose metabolism during and after pregnancy in normal and gestational diabetic women. Influence of normal pregnancy on serum glucose and insulin concentration during basal fasting conditions and after a challenge with glucose. Acta Endocrinol Copenh 1975; 79:709–19.Search in Google Scholar
17 Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144:768–73.10.1016/0002-9378(82)90349-0Search in Google Scholar
18 Moses R, Webb AJ, Lucas EM, Davis WS. Twin pregnancy outcome for women with gestational diabetes mellitus compared with glucose tolerant women. Aust N Z J Obstet Gynaecol 2003; 43:38–4010.1046/j.0004-8666.2003.00015.xSearch in Google Scholar
19 Banauch D, Brummer W, Ebeling W, Metz H, Rindfrey H, Lang H, et al. Eine Glucose-Dehydrogenase für die Glucosebestimmung in Korperflüssigkeiten. Z Klin Chem Klin Biochem 1975; 13:101–7.Search in Google Scholar
20 Stahl M, Brandslund I, Iversen S, Filtenborg JA. Quality assessment of blood glucose testing in general practitioners’ office improves quality. Clin Chem 1997; 43:1926–31.10.1093/clinchem/43.10.1926Search in Google Scholar
21 Morishima HO. Virginia Apgar (1909–1974). J Pediatr 1996; 129:768–70.10.1016/S0022-3476(96)70170-1Search in Google Scholar
22 Gardner MJ, Altman DG. Calculating confidence intervals for proportions and their differences. In: Gardner MJ, Altman DG, editors. Statistics with confidence. Confidence intervals and statistical guidelines. London: BMJ Books, 1992.Search in Google Scholar
23 European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diab Med 1999; 16:716–30. (http://www.staff.ncl.ac.uk/philip.home/guidelines).10.1046/j.1464-5491.1999.00166.xSearch in Google Scholar
24 Jørgensen LGM, Schytte T, Brandslund I, Stahl M, Hyltoft Petersen P, Andersen B. The fasting and post glucose load reference limit of peripheral venous plasma glucose in pregnant women Clin Chem Lab Med 2003; 41:187–99.10.1515/CCLM.2003.031Search in Google Scholar PubMed
25 Sacks DA, Chen W, Wolde-Tsadik G, Buchanan TA. Fasting plasma glucose test at the first prenatal visit as a screen for gestational diabetes. Obstet Gynecol 2003; 101:1197–203.Search in Google Scholar
26 Westerway SC, Keogh J, Heard R, Morris J. Incidence of fetal macrosomia and birth complications in Chinese immigrant women. Aus N Z J Obstet Gynaecol 2003; 43:46–9.10.1046/j.0004-8666.2003.00013.xSearch in Google Scholar PubMed
27 Wagaarachchi PT, Fernando L, Premachadra P, Fernando JS. Screening based on risk factors for gestational diabetes in an Asian population. J Obstet Gynecol 2001; 21:32–4.10.1080/01443610020022087Search in Google Scholar PubMed
28 Brody SC, Harris R, Lohr K. Screening for gestational diabetes: a summary of the evidence for the US preventive service task force. Obstet Gynecol 2003; 101:380–92.10.1097/00006250-200302000-00027Search in Google Scholar
29 Stahl M, Jørgensen LGM, Hyltoft Petersen P, Brandslund I, de Fine Olivarius N, Borch-Johnsen K. Optimization of preanalytical conditions and analysis of plasma glucose. 1. The impact of the new WHO and ADA recommendations on the diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61:169–80.10.1080/003655101300133612Search in Google Scholar PubMed
30 Jørgensen LGM, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. The plasma glucose reference interval in a low-risk population. 2. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001; 61:181–90.10.1080/003655101300133621Search in Google Scholar PubMed
31 Hyltoft Petersen P, Brandslund I, Jørgensen LGM, Stahl M, de Fine Olivarius N, Borch-Johnsen K. Evaluation of systematic and random factors in measurements of fasting plasma glucose as basis for analytical quality specifications for the diagnosis of diabetes. 3. The impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus diabetes. Scand J Clin Lab Invest 2001; 61:191–204.Search in Google Scholar
© Walter de Gruyter
